Trevi Therapeutics (TRVI) Total Non-Current Liabilities (2020 - 2022)
Trevi Therapeutics' quarterly Total Non-Current Liabilities came in at $15.6 million in Q4 2022, down 26.93% year-on-year from $21.3 million in Q4 2021, and down 15.67% quarter-over-quarter from $18.4 million in Q3 2022.
Trevi Therapeutics has reported Total Non-Current Liabilities for 3 years, with the latest figure at $15.6 million in Q4 2022.
- For the quarter ending Q4 2022, Total Non-Current Liabilities fell 26.93% year-over-year to $15.6 million; the trailing twelve-month figure through Dec 2022 stood at $15.6 million (down 26.93% YoY), and the FY2022 full-year result was $15.6 million, down 26.93% from the prior year.
- Total Non-Current Liabilities for Q4 2022 stood at $15.6 million, down from $18.4 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $21.3 million in Q4 2021, with the low at $15.6 million in Q4 2022.
- Average Total Non-Current Liabilities over 3 years is $19.6 million, with a median of $19.9 million recorded in 2021.
- Year-over-year, Total Non-Current Liabilities increased 8.31% in 2021 and declined 26.93% in 2022.
- Tracing TRVI's Total Non-Current Liabilities over 3 years: stood at $19.7 million in 2020, then climbed by 8.31% to $21.3 million in 2021, then dropped by 26.93% to $15.6 million in 2022.
- The last three Total Non-Current Liabilities figures came in at $15.6 million (Q4 2022), $18.4 million (Q3 2022), and $20.9 million (Q2 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 15.55 Mn |
| Sep 30, 2022 | 18.44 Mn |
| Jun 30, 2022 | 20.86 Mn |
| Mar 31, 2022 | 19.80 Mn |
| Dec 31, 2021 | 21.29 Mn |
| Sep 30, 2021 | 20.05 Mn |
| Jun 30, 2021 | 21.25 Mn |
| Mar 31, 2021 | 18.98 Mn |
| Dec 31, 2020 | 19.65 Mn |
| Sep 30, 2020 | 20.07 Mn |